Targeting immunogenic cell death for glioma immunotherapy
/in Dendritic Cells, Glioblastoma, Immunogenic Cell Death, International Publications /von 2023-11-14 / Trends Cancer 2024 Jan;10(1):8-11Therapeutic cell-based vaccines for glioblastoma multiforme
/in Dendritic Cells, Glioblastoma, International Publications /von 2023-11-12 / Med Oncol 2023 Nov;40(12):354Methods behind oncolytic virus-based DC vaccines in cancer: Toward a multiphase combined treatment strategy for Glioblastoma (GBM) patients
/in Dendritic Cells, Glioblastoma, Hyperthermia, International Publications, IOZK Aktuelles, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2023-10-19 / Methods Cell Biol 2024;183:51-113Clinical Applications of Immunotherapy for Recurrent Glioblastoma in Adults
/in Dendritic Cells, Glioblastoma, International Publications, Newcastle Disease Virus /von 2023-07-31 / Cancers (Basel) 2023 Jul;15(15)Dendritic cell vaccination for glioblastoma multiforme patients: has a new milestone been reached?
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Aktuelles, IOZK Veröffentlichungen /von 2023-07-28 / Transl Cancer Res 2023 Aug;12(8):2224-2228Recent oncolytic virotherapy clinical trials outline a roadmap for the treatment of high-grade glioma
/in Brain Tumors in Children, Glioblastoma, International Publications, Newcastle Disease Virus /von 2023-07-07 / Neurooncol Adv 2023;5(1):vdad081Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines
/in Dendritic Cells, Glioblastoma, International Publications, Malignant Melanoma /von 2023-05-03 / Hum Vaccin Immunother 2023 May;:2198467Combination immunotherapy of glioblastoma with dendritic cell cancer vaccines, anti-PD-1 and poly I:C
/in Dendritic Cells, Glioblastoma, International Publications /von 2023-04-21 / J Pharm Anal 2023 Jun;13(6):616-624The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2023-04-03 / Pharmaceutics 2023 Apr;15(4)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de